Canaccord analyst William Plovanic raised the firm’s price target on ShockWave Medical to $252 from $247 and keeps a Buy rating on the shares. The analyst said Q4 US coronary revenue missed our estimate, with peripheral and OUS coronary taking over as growth drivers going forward. Shockwave reiterated its strong 2023 revenue guidance, which was well ahead of consensus when issued in late January.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SWAV:
- ShockWave Medical reports Q4 EPS $3.71, consensus $1.00
- Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results
- ShockWave Medical announces coronary IVL included as treatment option by SCAI
- ShockWave Medical price target lowered to $280 from $300 at Piper Sandler
- ShockWave Medical to acquire Neovasc for $27.25 per share